{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT05885464","orgStudyIdInfo":{"id":"BTX-ALO-001"},"organization":{"fullName":"Beam Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","officialTitle":"A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)"},"statusModule":{"statusVerifiedDate":"2025-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-05-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-05-23","studyFirstSubmitQcDate":"2023-06-01","studyFirstPostDateStruct":{"date":"2023-06-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-10","lastUpdatePostDateStruct":{"date":"2025-01-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Beam Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \\< 12 years), and a Phase 2 cohort."},"conditionsModule":{"conditions":["Lymphoblastic Lymphoma","T-Cell Lymphoblastic Leukemia/Lymphoma","Lymphoblastic Leukemia"],"keywords":["Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Base editing","CAR-T"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"The maximum number of patients for this study is approximately 102 patients:\n\n* 36 patients in the Phase 1 dose exploration\n* approximately 12 patients in the Phase 1 dose-expansion cohorts\n* 6 patients in the pediatric cohort\n* approximately 48 patients in the Phase 2 cohort.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":5,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Fludarabine, cyclophosphamide and alemtuzumab","type":"EXPERIMENTAL","description":"Lymphodepletion regimen including fludarabine, cyclophosphamide and alemtuzumab","interventionNames":["Biological: BEAM-201"]},{"label":"Fludarabine, cyclophosphamide without alemtuzumab","type":"EXPERIMENTAL","description":"Lymphodepletion regimen without Alz but consisting of the same dose of Flu/Cy as in the other arm","interventionNames":["Biological: BEAM-201"]}],"interventions":[{"type":"BIOLOGICAL","name":"BEAM-201","description":"A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens","armGroupLabels":["Fludarabine, cyclophosphamide and alemtuzumab","Fludarabine, cyclophosphamide without alemtuzumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only)","timeFrame":"Through study completion, an average of 25 months"},{"measure":"Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusion","timeFrame":"From treatment with BEAM-201 through study completion"}],"secondaryOutcomes":[{"measure":"Proportion of patients who achieve MRD negative response (defined as < 0.1%) by flow cytometry or next generation sequencing (NGS) in patients achieving morphologic response","timeFrame":"Starting at Day 28 and multiple time points up to Month 24"},{"measure":"Proportion of patients treated with BEAM-201 deemed appropriate for HSCT based on investigator assessment of clinical response","timeFrame":"Through study completion, an average of 25 months"},{"measure":"Duration of Response (DOR)","timeFrame":"Through study completion, an average of 25 months"},{"measure":"Relapse-free survival (RFS)","timeFrame":"Through study completion, an average of 25 months"},{"measure":"Overall survival","timeFrame":"Through study completion, an average of 25 months"},{"measure":"Relapse-related mortality","timeFrame":"Through study completion, an average of 25 months"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Ages 18 to ≤ 50 years.\n2. Ages ≥ 1 year to \\< 18 years, after health authority approval.\n3. T-ALL/T-LL that is CD7-positive (defined as at least 20% of blasts positive for CD7 by flow cytometry or immunohistochemistry based on assessment of the study site's CLIA \\[Clinical Laboratory Improvement Amendments of 1988\\] certified facility) in second or greater relapse, first relapse post-transplant relapse, or chemotherapy-refractory disease. Specifically:\n\n   1. Second or greater relapse or post-transplant relapse, defined as:\n\n      * BM with ≥ 5% lymphoblasts by morphologic assessment or evidence of extramedullary disease at screening after second documented CR; OR\n      * Flow cytometric confirmation of relapsed T-ALL of at least 0.1% after second CR documented to have been MRD negative \\< 0.1%; OR\n      * Any detectable relapsed disease post-allogeneic HSCT with flow cytometric confirmation of T-ALL of at least 0.1%; OR\n      * Biopsy confirmed evidence of relapsed T-LL on lymph node biopsy after second CR; OR\n      * Any detectable disease post-allogeneic transplant with biopsy confirmed evidence of T-LL on lymph node biopsy\n   2. Refractory disease, defined as:\n\n      * Primary refractory T-ALL or T-LL, defined as failure to achieve CR after induction chemotherapy, per investigator assessment and based on biopsy-confirmed evidence of residual T-ALL or T-LL; OR\n      * Relapsed, refractory disease, defined as \\> 5% BM blasts or biopsy-confirmed evidence of residual TLL after 1 course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR NOTE: Patients with mixed phenotype acute leukemia with T-cell dominant phenotype may be enrolled if the aforementioned criteria are met.\n4. Eligible for myeloablative conditioning for and allogeneic HSCT based on the investigator's assessment with an available donor identified by a FACT accredited transplant center.\n\nKey Exclusion Criteria:\n\n1. CNS involvement meeting any of the following criteria: CNS-3 disease, progressive CNS involvement despite therapy, CNS parenchymal or cranial nerve lesions on imaging.\n2. Clinically active CNS dysfunction or known history of irreversible neurological toxicity related to prior antileukemic therapy.\n3. Receipt of prior CD7 targeted therapy.\n4. Systemic antileukemic therapy intended to induce or maintain remission within 14 days prior to completion of screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Stanford University School of Medicine","city":"Stanford","state":"California","zip":"94304","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}},{"facility":"Colorado Blood Cancer Institute","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"University of Chicago","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"The University of Kansas Cancer Center","city":"Fairway","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.02223,"lon":-94.6319}},{"facility":"Dana Farber and Boston Children's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Cleveland Clinic- Taussig Cancer Center","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"OHSU Knight Cancer Institute Hematology Oncology","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Children's Hospital of Philadelphia","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Sarah Cannon- TriStar Bone Marrow Transplant","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Methodist Hospital - Texas Transplant Institute","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D054198","term":"Precursor Cell Lymphoblastic Leukemia-Lymphoma"},{"id":"D008223","term":"Lymphoma"}],"ancestors":[{"id":"D007945","term":"Leukemia, Lymphoid"},{"id":"D007938","term":"Leukemia"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06071377","orgStudyIdInfo":{"id":"AUNT"},"organization":{"fullName":"National Alliance for Sickle Cell Centers","class":"OTHER"},"briefTitle":"Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)","officialTitle":"Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-04-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-09-26","studyFirstSubmitQcDate":"2023-10-04","studyFirstPostDateStruct":{"date":"2023-10-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-04","lastUpdatePostDateStruct":{"date":"2025-11-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Alliance for Sickle Cell Centers","class":"OTHER"},"collaborators":[{"name":"Beam Therapeutics Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT."},"conditionsModule":{"conditions":["Sickle Cell Trait"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"For individuals who consent to provide optional DNA testing, an alpha globin sequencing (ATHAL) test will be included."},"enrollmentInfo":{"count":1000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Individuals with sickle cell trait","interventionNames":["Other: Biologic Specimen Collection"]}],"interventions":[{"type":"OTHER","name":"Biologic Specimen Collection","description":"Participants will have blood and urine collected at Baseline","armGroupLabels":["Individuals with sickle cell trait"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Hemoglobin variant quantification","description":"Determine range of variability in baseline %HbS in SCT subjects and relationship of baseline %HbS to markers of hemolysis (LDH, reticulocytes, haptoglobin), coagulopathy (D-dimer), and renal disease (urine albumin/creatinine ratio)","timeFrame":"Through study completion, an average of 2 years"}],"secondaryOutcomes":[{"measure":"Red blood cell rheology","description":"Identify range of variation in baseline RBC rheological parameters in SCT subjects and relationship to %HbS, other baseline clinical parameters","timeFrame":"Through study completion, an average of 2 years"},{"measure":"Natural History","description":"Evaluate the frequency of hemolysis\n\n* Evaluate potential for and progression of chronic kidney disease and albuminuria\n* Evaluate the relative risk of thrombosis based on medical history\n* Evaluate the prevalence of episodes of pain or exercise-related symptoms","timeFrame":"Through study completion, an average of 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Are willing to voluntarily participate and sign the study consent\n2. Know/suspect they have SCT and are willing to get tested to confirm/learn about their SCT status\n3. Adults ages 18 and older\n\nExclusion Criteria:\n\n1. Unwilling to sign consent\n2. Known end-stage renal disease or dialysis\n3. Known SCD (including sickle cell-beta thalassemia)\n4. People who do not have SCT","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Adults aged 18 and older with sickle cell trait.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Julie Kanter, MD","role":"CONTACT","phone":"(202) 596-1548","email":"jkanter@sicklecellcenters.org"}],"overallOfficials":[{"name":"Julie Kanter, MD","affiliation":"National Alliance for Sickle Cell Centers","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Alabama","status":"RECRUITING","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","contacts":[{"name":"Marteesa William Oliver","role":"CONTACT","email":"marteesawilliams@uabmc.edu"},{"name":"Julie Kanter","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Loma Linda University Health Care","status":"RECRUITING","city":"Loma Linda","state":"California","zip":"92354","country":"United States","contacts":[{"name":"Monica Pizana","role":"CONTACT","email":"mpizana@llu.edu"},{"name":"Akshat Jain","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.04835,"lon":-117.26115}},{"facility":"Nemours Children's Hospital","status":"RECRUITING","city":"Wilmington","state":"Delaware","zip":"19803","country":"United States","contacts":[{"name":"Nicole Wittmeyer","role":"CONTACT","email":"Nicole.Wittmeyer@nemours.org"},{"name":"Robin Miller, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.74595,"lon":-75.54659}},{"facility":"Indiana University","status":"RECRUITING","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","contacts":[{"name":"Claire Kendrick","role":"CONTACT","email":"cjkendri@iu.edu"},{"name":"Andrew O'Brien","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Functional Fluidics","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","contacts":[{"name":"Jennell White, PhD","role":"CONTACT","email":"jennell.white@functionalfluidics.com"},{"name":"Ifeoma Iwuagwu","role":"CONTACT","email":"ifeoma.iwuagwu@functionalfluidics.com"},{"name":"Patrick Hines, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"University of North Carolina","status":"RECRUITING","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","contacts":[{"name":"David Wichlan","role":"CONTACT","email":"david_wichlan@med.unc.edu"},{"name":"Patrick Ellison","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Duke University","status":"RECRUITING","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","contacts":[{"name":"Morgan Low","role":"CONTACT","email":"morgan.low@duke.edu"},{"name":"JJ Strouse, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"East Carolina University","status":"RECRUITING","city":"Greenville","state":"North Carolina","zip":"27834","country":"United States","contacts":[{"name":"Sean Segre","role":"CONTACT","email":"segres24@ecu.edu"},{"name":"Beng Fuh","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.61266,"lon":-77.36635}},{"facility":"Nationwide Children's Hospital","status":"RECRUITING","city":"Columbus","state":"Ohio","zip":"43205","country":"United States","contacts":[{"name":"Tiffany Rosetti","role":"CONTACT","email":"Tiffany.Rossetti@nationwidechildrens.org"},{"name":"Anthony Villella, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"UT Health Houston","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Amanda Gregg","role":"CONTACT","email":"amanda.gregg@uth.tmc.edu"},{"name":"Idowu Modupe, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D012805","term":"Sickle Cell Trait"}],"ancestors":[{"id":"D000755","term":"Anemia, Sickle Cell"},{"id":"D000745","term":"Anemia, Hemolytic, Congenital"},{"id":"D000743","term":"Anemia, Hemolytic"},{"id":"D000740","term":"Anemia"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D006453","term":"Hemoglobinopathies"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"}]}},"hasResults":false}
]}